These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12531322)

  • 1. New tendencies and strategies in international immunisation: GAVI and The Vaccine Fund.
    Martin JF; Marshall J
    Vaccine; 2003 Jan; 21(7-8):587-92. PubMed ID: 12531322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
    Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
    Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of the GAVI Alliance to improving health and reducing poverty.
    Lob-Levyt J
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2743-7. PubMed ID: 21893535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Global Alliance for Vaccines and Immunization: is it a new model for effective public-private cooperation in international public health?
    Muraskin W
    Am J Public Health; 2004 Nov; 94(11):1922-5. PubMed ID: 15514228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines, global health and social equity.
    Levine MM; Robins-Browne R
    Immunol Cell Biol; 2009; 87(4):274-8. PubMed ID: 19308074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GAVI, the first steps: lessons for the Global Fund.
    Brugha R; Starling M; Walt G
    Lancet; 2002 Feb; 359(9304):435-8. PubMed ID: 11844535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring what governments "give for" and "spend on" vaccine procurement: Vaccine Procurement Assistance and Vaccine Procurement Baseline.
    Nelson EA; Bloom DE; Mahoney RT
    PLoS One; 2014; 9(2):e89593. PubMed ID: 24586899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.
    Kamara L; Milstien JB; Patyna M; Lydon P; Levin A; Brenzel L
    Vaccine; 2008 Dec; 26(51):6717-26. PubMed ID: 18955100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GAVI Financing Task Force: one model of partner collaboration.
    Milstien JB; Kamara L; Lydon P; Mitchell V; Landry S
    Vaccine; 2008 Dec; 26(51):6699-705. PubMed ID: 19306508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs of scaling up vaccination in the world's poorest countries.
    Bishai D; McQuestion M; Chaudhry R; Wigton A
    Health Aff (Millwood); 2006; 25(2):348-56. PubMed ID: 16522576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
    Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
    Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
    Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
    Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World Health Organization perspectives on the contribution of the Global Alliance for Vaccines and Immunization on reducing child mortality.
    Bustreo F; Okwo-Bele JM; Kamara L
    Arch Dis Child; 2015 Feb; 100 Suppl 1():S34-7. PubMed ID: 25613965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunisation strategies for viral diseases in developing countries.
    Ruff TA
    Rev Med Virol; 1999; 9(2):121-38. PubMed ID: 10386339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GAVI and the Vaccine Fund--a boon for immunization in the developing world.
    Balaji KA
    Indian J Public Health; 2004; 48(2):45-8. PubMed ID: 15709583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postneonatal mortality impacts following grants from the Gavi Vaccine Alliance: an econometric analysis from 2000 to 2014.
    Kolesar RJ; Audibert M
    Public Health; 2017 Dec; 153():163-171. PubMed ID: 29102832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.